340 related articles for article (PubMed ID: 21139544)
1. Management of pancreatic neuroendocrine tumors.
Dabizzi E; Panossian A; Raimondo M
Minerva Gastroenterol Dietol; 2010 Dec; 56(4):467-79. PubMed ID: 21139544
[TBL] [Abstract][Full Text] [Related]
2. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours.
Oberg K
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S17-25. PubMed ID: 22005113
[No Abstract] [Full Text] [Related]
3. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
4. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):357-360. PubMed ID: 28338171
[TBL] [Abstract][Full Text] [Related]
5. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C
Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573
[TBL] [Abstract][Full Text] [Related]
6. [Neuroendocrine tumors of the digestive system].
Prónai L; Rácz K; Tulassay Z
Orv Hetil; 2002 May; 143(19 Suppl):1081-6. PubMed ID: 12063866
[TBL] [Abstract][Full Text] [Related]
7. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
Singh S; Law C
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
[TBL] [Abstract][Full Text] [Related]
8. Measurements of chromogranin B can serve as a complement to chromogranin A.
Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
[TBL] [Abstract][Full Text] [Related]
9. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
10. Selective expression of trophoblastic hormones by lung carcinoma: neurendocrine tumors exclusively produce human chorionic gonadotropin alpha-subunit (hCGalpha).
Dirnhofer S; Freund M; Rogatsch H; Krabichler S; Berger P
Hum Pathol; 2000 Aug; 31(8):966-72. PubMed ID: 10987258
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
12. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.
Modlin IM; Gustafsson BI; Moss SF; Pavel M; Tsolakis AV; Kidd M
Ann Surg Oncol; 2010 Sep; 17(9):2427-43. PubMed ID: 20217257
[TBL] [Abstract][Full Text] [Related]
13. Are biochemical markers of neuroendocrine tumors coreleased with insulin following local calcium stimulation in patients with insulinomas?
Wiesli P; Uthoff H; Perren A; Pfammatter T; Zwimpfer C; Seiler H; Kindhauser R; Spinas GA; Schmid C
Pancreas; 2011 Oct; 40(7):995-9. PubMed ID: 21705951
[TBL] [Abstract][Full Text] [Related]
14. [Chromogranin A and neuroendocrine tumors].
Díaz Pérez JÁ; Currás Freixes M
Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
[TBL] [Abstract][Full Text] [Related]
15. Endocrine tumors of the pancreas.
Simon P; Spilcke-Liss E; Wallaschofski H
Endocrinol Metab Clin North Am; 2006 Jun; 35(2):431-47, xii. PubMed ID: 16632104
[TBL] [Abstract][Full Text] [Related]
16. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.
Janson ET; Sørbye H; Welin S; Federspiel B; Grønbaek H; Hellman P; Mathisen O; Mortensen J; Sundin A; Thiis-Evensen E; Välimäki MJ; Oberg K; Knigge U
Acta Oncol; 2010 Aug; 49(6):740-56. PubMed ID: 20553100
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine tumors of the pancreas.
Milan SA; Yeo CJ
Curr Opin Oncol; 2012 Jan; 24(1):46-55. PubMed ID: 22080942
[TBL] [Abstract][Full Text] [Related]
18. Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients.
de Laat JM; Pieterman CR; Weijmans M; Hermus AR; Dekkers OM; de Herder WW; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Vriens MR; Valk GD
J Clin Endocrinol Metab; 2013 Oct; 98(10):4143-51. PubMed ID: 23956349
[TBL] [Abstract][Full Text] [Related]
19. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
20. GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers.
Verbeek WH; Korse CM; Tesselaar ME
Eur J Endocrinol; 2016 Jan; 174(1):R1-7. PubMed ID: 26162406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]